Tisagenlecleucel 治疗儿童急性淋巴细胞白血病及非霍奇金淋巴瘤的真实世界证据
基于细胞治疗登记处数据,截至2020年1月纳入73个中心的511例患者,410例有随访数据(ALL 255例,NHL 155例)。NHL最佳总缓解率61.8%,初始完全缓解率39.5%,6个月缓解持续时间、无进展生存率和总生存率分别为55.3%、38.7%和70.7%。
要点
- 真实世界中tisagenlecleucel治疗ALL和NHL的疗效与关键试验相似,安全性更优。
- ≥3级细胞因子释放综合征和神经毒性发生率分别为11.6%和7.5%。
核心结论
- 真实世界数据显示tisagenlecleucel治疗儿童ALL和成人NHL的疗效与关键试验相似,且安全性改善。
研究设计与样本
- 基于细胞治疗登记处的真实世界研究,截至2020年1月纳入73个中心的511例患者,410例有随访数据(ALL 255例,NHL 155例)。
- ALL中位随访13.4个月,NHL中位随访11.9个月。
主要发现
- ALL患者初始完全缓解率为85.5%。
- NHL患者最佳总缓解率为61.8%,初始完全缓解率为39.5%。
- NHL患者6个月缓解持续时间、无进展生存率和总生存率分别为55.3%、38.7%和70.7%。
- 所有患者中≥3级细胞因子释放综合征和神经毒性发生率分别为11.6%和7.5%。
关键数值与推荐
- NHL最佳总缓解率61.8%,初始完全缓解率39.5%,6个月DOR 55.3%、PFS 38.7%、OS 70.7%。
- ≥3级细胞因子释放综合征发生率11.6%,≥3级神经毒性发生率7.5%。
- 因活力<80%(范围61%至79%)导致的不符合规格产品与符合规格产品的结局相似。
临床怎么用
- 真实世界中使用tisagenlecleucel可参考本研究的疗效和安全性数据。
- 产品活力低于80%时仍可能获得与符合规格产品相似的结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Tisagenlecleucel is a CD19 chimeric antigen receptor (CAR) T-cell therapy approved for treatment of pediatric and young adult patients with relapsed/refractory acute lymphoblastic leukemia (ALL) and adults with non-Hodgkin lymphoma (NHL). The initial experience with tisagenlecleucel in a real-world setting from a cellular therapy registry is presented here. As of January 2020, 511 patients were enrolled from 73 centers, and 410 patients had follow-up data reported (ALL, n = 255; NHL, n = 155), with a median follow-up of 13.4 and 11.9 months for ALL and NHL, respectively. Among patients with ALL, the initial complete remission (CR) rate was 85.5%. Twelve-month duration of response (DOR), event-free survival, and overall survival (OS) rates were 60.9%, 52.4%, and 77.2%, respectively. Among adults with NHL, the best overall response rate was 61.8%, including an initial CR rate of 39.5%. Six-month DOR, progression-free survival, and OS rates were 55.3%, 38.7%, and 70.7%, respectively. Grade ≥3 cytokine release syndrome and neurotoxicity were reported in 11.6% and 7.5% of all patients, respectively. Similar outcomes were observed in patients with in-specification and out-of-specification products as a result of viability <80% (range, 61% to 79%). This first report of tisagenlecleucel in the real-world setting demonstrates outcomes with similar efficacy and improved safety compared with those seen in the pivotal trials.
引用
- Pasquini MC, Hu ZH, Curran K, et al. Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma. Blood Adv. 2020. PMID: 33147337. doi:10.1182/bloodadvances.2020003092
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。